UK Approves First Crispr Gene Edited Therapy For Sickle Cell Disease, Beta Thalassemia

UK Approves First Crispr Gene Edited Therapy For Sickle Cell Disease, Beta Thalassemia

Upworthy

Published

The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for Casgevy (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). There are an…

#ukmedicines #healthcare #scd #tdt #greatbritain #crispr #vertex #vrtx #crsp

Full Article